Organovo Holdings, Inc. is a clinical-stage biotechnology company. The Company is developing drugs that are demonstrated to be effective in three-dimensional (3D) human tissues as candidates for drug development. It focuses on developing novel treatment approaches in inflammatory bowel disease (IBD). The Company has proprietary technology used to build 3D human tissues that mimic key aspects of native human tissue composition, architecture, function, and disease. It uses its proprietary technology to build functional 3D human tissues that mimic key aspects of native human tissue composition, architecture, function, and disease. Its Mosaic division to serve as a key source of certain primary human cells it utilizes in its research and development efforts. Its 3D human tissue platform is multifaceted. Its NovoGen Bioprinters can also dispense pure hydrogel formulations, provided the physical properties of the hydrogel are compatible with the dispensing parameters.